Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Biogen is paying Sangamo Therapeutics $350 million up front to develop gene therapies for neurological diseases. The deal focuses on Sangamo’s zinc finger protein transcription factors (ZFP-TFs), which dial the expression of genes up or down. The two most advanced programs in the collaboration use ZFP-TFs to decrease levels of tau proteins and α-synuclein proteins, implicated in Alzheimer’s and Parkinson’s disease, respectively. Biogen has exclusive rights to develop Sangamo’s ZFP-TFs for up to 10 additional targets.
This article has been sent to the following recipient: